IKT News and Press, Inhibikase Therapeutics Inc. From 09/23/21

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy PR Newswire ATLANTA , Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "C...

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire ATLANTA , Sept. 7, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developin...

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity PR Newswire ATLANTA , Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company ...

IRSA Propiedades Comerciales (IRCP) -69%.Infinity Pharmaceuticals (INFI) -23% on Q2 earnings release and updates data from bladder and breast cancer trials.TRxADE HEALTH (MEDS) -20% on Q2 earnings release.Bit Digital (BTBT) -17%.Flora Growth (FLGC) -15% to f...

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients PR Newswire ATLANTA , July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pha...

Gainers: Clene (CLNN) +8%, Inhibikase Therapeutics (IKT) +7%, ASLAN Pharmaceuticals (ASLN) +5%, Doximity (DOCS) +5%.Losers: IMV (IMV) -26%, Tempest Therapeutics (TPST) -25%, Sonoma Pharmaceuticals (SNOA) -23%, Immunic (IMUX) -18%, Virpax ...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks fell for a fourth straight day, and the S&P 500 finished its worst week since February, after St. Louis Federal Reserve President ...

Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock PR Newswire ATLANTA , June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics ...

Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...

Inhibikase Therapeutics (IKT) -24% after prices stock offering at $3Blue Apron Holdings (APRN) -19% after announcing share offering.Alfi (ALF) -14%.Clearside Biomedical (CLSD) -10%.TAL Education (TAL) -10%.TDH Holdings (PETZ) -10%.Unique Fabricating (UFAB) -9%.Roblox (RBLX...